Sullivan Lara 4

4 · Pyxis Oncology, Inc. · Filed Mar 28, 2023

Form 4

Period: 2023-03-24

DirectorPresident ,CEO & CMO

Transactions

Award
Common Stock
2023-03-24+703,379→ 2,155,699 total
Disposition to Issuer
Stock Option (Right to buy)
2023-03-24−990,461→ 0 total
Exercise: $5.34Exp: 2031-03-30→ Common Stock (990,461 underlying)
Award
Stock Option (Right to buy)
2023-03-24+990,461→ 990,461 total
Exercise: $2.21Exp: 2031-03-30→ Common Stock (990,461 underlying)
Award
Stock Option (Right to buy)
2023-03-24+61,825→ 61,825 total
Exercise: $2.21Exp: 2031-09-14→ Common Stock (61,825 underlying)
Disposition to Issuer
Stock Option (Right to buy)
2023-03-24−61,825→ 0 total
Exercise: $8.71Exp: 2031-09-14→ Common Stock (61,825 underlying)

Footnotes (4)

[F1]Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
[F2]In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.
[F3]These stock options vest in 48 substantially-equal monthly installments beginning January 2, 2020, subject to the reporting person's continued employment through the applicable vesting date.
[F4]These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

Documents

1 file